Curated gurus reporting this holding
A curated subset of well-known investors — not the full institutional ownership.
- Bridgewater Associates429,904주2026-06-30 · 증감 +118489주
$52.19-3.19%
2026-10-06 close · prelimTG Therapeutics's company information is shown as of 2026-10-06. It is a security listed on Nasdaq, ticker TGTX. There are 14 published related companies.
About this company
TG Therapeutics last closed at $52.19 (-3.19%) on 2026-10-06. Listed on Nasdaq.
Who held it · filings
Filed recordA historical record from curated-guru 13F filings and DART 5%+ major-holding disclosures.
US 13F is quarterly and may be filed up to 45 days later.
Suppliers, competitors and related stocks
- RocheCompetitor
B세포질환·다발성경화증 등에서 TG Therapeutics와 치료제 경쟁
- NovartisCompetitor
MS 치료제 시장의 글로벌 경쟁사
- BiogenCompetitor
재발성 다발성경화증 등에서 직접 경쟁
- SanofiCompetitor
자가면역·혈액암 치료 영역에서 경쟁
- AbbVieCompetitor
혈액암·면역질환 치료제 시장의 대형 경쟁사
- AmgenCompetitor
혈액암 및 면역질환 치료제에서 경쟁
- Gilead SciencesCompetitor
항암·면역치료 영역에서 경쟁
- AstraZenecaCompetitor
혈액암 파이프라인 및 면역질환에서 경쟁
- UCBCompetitor
면역질환 치료제 시장의 경쟁사
- Johnson & JohnsonCompetitor
혈액암·면역질환 대형 제약사로 경쟁
- Fresenius KabiSupplier
주사제·병원용 의약품 공급망에서 연관 가능성이 큰 글로벌 의약품 공급사
- AmgenSupplier
TG Therapeutics의 항체의약품 개발·제조 생태계에서 바이오의약품 협력/공급망 측면 관련
- Multiple sclerosisRelated theme
TG Therapeutics의 핵심 치료영역인 다발성경화증 테마
- B-cell malignanciesRelated theme
TG Therapeutics의 핵심 혈액암 테마
Major stocks in the same sector
2026-10-06 dataset
📦 ETFs holding this stock
by weight · top-10 constituents basisPassive money holding this stock ≈ $12M(lower bound — top-10 basis, not a forecast)
- Innovator IBD Breakout Opportunities ETF7.01%
- Invesco S&P SmallCap Health Care ETF3.65%
- Innovator IBD 50 ETF3.51%
- ETC 6 Meridian Low Beta Equity ETF0.77%
Factual holdings info from daily disclosures — not a recommendation.
Look up another stock →Quantus Signal · live data · not investment advice · Privacy Policy